0 Items
Select Page

Streptococcus pneumoniae

Streptococcus pneumoniae is a major cause of morbidity and mortality, globally causing more deaths than any other infectious disease. At highest risk are the smallest children and elderly, with approximately one million children below 5 years of age dying, annually (CDC). Pneumococcal diseases range from mild respiratory tract mucosal infections, such as sinusitis, to more severe diseases such as pneumonia, septicaemia and meningitis.

The Native Antigen Company are committed to supporting research into Streptococcus, offering specific monoclonal antibodies to this bacterium.

Streptococcus Background

Streptococcus pneumoniae is a lancet-shaped, gram-positive, facultative anaerobic bacterium. In humans, S. pneumoniae primarily colonizes the nasopharynx and transmission occurs from person-to-person via respiratory secretions from patients infected wit, S. pneumoniae, and from healthy carriers. In susceptible individuals, the bacteria can spread to the lower respiratory tract, the inner ear or sinuses, to cause a range of illnesses, referred to as pneumococcal disease.

Worldwide, S. pneumoniae is the major cause of pneumonia, sepsis, and meningitis and the leading cause of community-acquired pneumonia in young children and the elderly.

Streptococcus pneumoniae Antibodies

The Native Antigen Company are pleased to offer a pair of monoclonal antibodies that are specific to Streptococcus pneumoniae, which are suitable for use in the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Flavivirus NS1: A Short Introduction

In the first of a two-part series, we describe the structure of Flavivirus Non-Structural Protein 1 (NS1) and the role that it plays in viral pathogenesis. Flavivirus proteins Flaviviruses are single-stranded, enveloped RNA viruses, belonging to the Flaviviridae...

Paper Synopsis: ELISA formats and antibody quenching to reduce ZIKV cross-reactivity

While the 2015/16 Zika epidemic no longer makes the headlines, there remains a crucial need to accurately and reliably diagnose Zika virus (ZIKV) infection to identify and manage further outbreaks. However, high levels of cross-reactivity among cocirculating...

Viral Lysates for Diagnostic Research

We've recently expanded our range of native viral cell lysates to complement our highly pure recombinant antigens. Here, we explain how our lysates are made and their uses in infectious disease R&D.What are viral lysates? Put simply, viral lysates are extracts of...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

5 + 4 =

Live Customer Feedback